5/6 March 2024
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has announced the availability of four Japanese Pharmacopoeia (JP) drafts of General Tests and General Information related to Balances.
The following documents have been published on the PMDA website:
The PMDA also published a Briefing Note in which the key points of these four drafts are summarised. It is pointed out that the drafts "were developed by referring to the content and requirements provided in United States Pharmacopeia and European Pharmacopoeia."
It is planned to include the chapters in Supplement II to the Japanese Pharmacopoeia 18th edition.
Comments can be submitted until 31 March 2023. For this purpose, a form for comments has to be downloaded and sent by e-mail after it has been filled in.